TACSTD2 and metastatic neoplasm: In the present study, we demonstrated (for the first time, to the best of our knowledge) that (i) an increased GSE1/TACSTD2 expression ratio marks patients with PCa and that (ii) the interaction between GSE1 and TACSTD2 drives metastatic disease, castration resistance, and disease progression in patients with PCa.